BioVersys AG is a venturelab-backed biotechnology startup focused on creating drugs capable of overcoming bacterial resistance to existing antibiotics. Its lead work seeks to address the growing global threat of antibiotic-resistant infections by restoring or enhancing antibiotic efficacy. The company was founded by Dr. Marc Gitzinger (CEO) and Dr. Marcel Tigges (CSO), who lead a team committed to translating their science into clinically relevant therapies. BioVersys recently secured CHF 2.5 million in seed financing, providing the capital needed to progress its drug development pipeline. The fresh funds establish a foundation for the next stages of research and development and position the firm for future clinical milestones. No revenue, user metrics, or additional financial figures were disclosed, reflecting the company’s early, pre-commercial stage.

Total raised

$105M

Funding rounds

7

Latest round

Series C

Latest activity

May 2024